drugset
drugset / Trial / NCT02606682

Phase 1 Study of NPT200-11 in Healthy Subjects

NCT02606682 ↗

Phase 1 Completed 55 enrolled Neuropore Therapies Inc. UCB S.A. - Pharma Sector · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.

Timeline

Start
2015-07
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject NPT200-11 Unknown 15 mg Oral
Subject NPT200-11 Unknown 30 mg Oral
Subject NPT200-11 Unknown 60 mg Oral
Subject NPT200-11 Unknown 120 mg Oral
Subject NPT200-11 Unknown 240 mg Oral
Subject NPT200-11 Unknown 360 mg Oral
Subject NPT200-11 Unknown 480 mg Oral

Indications

No indication recorded.